Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vitae Pharmaceuticals (VTAE), a clinical-stage biotechnology company, announced the initiation of a Phase 1 single ascending dose clinical trial of VTP-43742, the company's wholly owned and potential first-in-class RORγt inhibitor for the treatment of autoimmune disorders, including psoriasis, multiple sclerosis, and various arthropathies, as well as rare and orphan disorders.
Subscribe to our email newsletter
This single ascending dose trial will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of VTP-43742 in healthy human volunteers, with results expected in the second half of 2015.
The Company also intends to initiate an overlapping Phase 1 multiple ascending dose, proof-of-concept clinical trial of VTP-43742 in the third quarter, which will include patients with moderate to severe psoriasis. Top-line clinical efficacy results from this second clinical trial are expected by the end of the year.
"The initiation of this Phase 1 study of our wholly owned first-in-class ROR?t inhibitor is a very important milestone both for Vitae and for patients afflicted with autoimmune disorders," said Dr. Richard Gregg, Chief Scientific Officer of Vitae.
"We believe that VTP-43742’s unique mechanism of action has the potential to provide patients with a safe, effective and convenient oral treatment option for a variety of autoimmune disorders."
VTP-43742 is Vitae Pharmaceuticals’ wholly owned product candidate for the treatment of a variety of autoimmune disorders. In preclinical studies, VTP-43742 demonstrated potent inhibition of IL-17 secretion from Th17 cells, was highly selective versus other ROR isotypes, and has a predicted human oral dosing schedule of once-a-day.
VTP-43742 also demonstrated superiority in an animal model of multiple sclerosis in direct comparison to an IL-17A monoclonal antibody.
Vitae has filed an Investigational New Drug Application with the U.S. Food and Drug Administration for VTP-43742 and initiated a Phase 1 single ascending dose clinical trial in healthy human volunteers to assess safety, tolerability, pharmacokinetics and pharmacodynamics.